FDA Approved: ZYTIGA — Supplemental Application (Janssen Biotech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ZYTIGA (abiraterone acetate) to expand its indication for metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Zytiga (abiraterone acetate)

Snippet

SUPPL AP for ZYTIGA (ABIRATERONE ACETATE)